IMMP - Immutep announces Japan granted second patent for cancer therapy

Clinical-stage biotech, Immutep Limited (NASDAQ:IMMP) announced on Friday that the Japanese Patent Office issued a second patent related to its experimental cancer therapy LAG525 co-developed by Swiss pharma giant Novartis (NYSE:NVS), The patent no. 7030750 titled “antibody molecules to LAG-3 and uses thereof” covers pharmaceutical compositions that include LAG525 for the treatment of cancer. LAG525 is a humanized form of IMP701, a LAG-3 targeting therapeutic antagonist antibody out-licensed to Novartis (NVS). LAG525 is currently undergoing Phase 1 and 2 clinical trials for cancer. Novartis (NVS) and Immutep (IMMP) co-own the patent, and it expires in March 2035. Immutep and CoStim Pharmaceuticals, which was later acquired by Novartis, signed a license and collaboration agreement in 2012 for IMP701.

For further details see:

Immutep announces Japan granted second patent for cancer therapy